In the two-stage GWAS stratified by tumor subtypes, rs166870 and rs10825036 were consistently associated with DFS in the HR+ HER2- and HR- HER2- breast cancer subtypes, respectively (Prs166870=2.88×10-7 and Prs10825036=3.54×10-7 in the combined set). Here, ERBB2 is linked to breast carcinoma.